EUCTR2015-002072-24-DE进行中（未招募）1 期
An Open-Label, Dose Finding, International Phase 2 Study with Once Monthly Subcutaneous Somavaratan (VRS-317) in Adult Growth Hormone Deficiency (GHD)Versartis International Trial in Adults with Long Acting Growth Hormone. The VITAL study - Versartis International Trial in Adults with Long Acting Growth Hormone (VITAL)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Female or male subjects with age 23 to 70 years (inclusive).
- •2. Female subjects of childbearing potential must agree to use appropriate contraceptive methods during the study and continue this method for at least one month after their study completion.
- •3. Female subjects of childbearing potential must have a negative serum pregnancy test at Screening.
- •4. Subjects must have a documented medical history of GHD during adulthood, according to established guidelines (confirmatory testing
- •should be done to document persistence of childhood onset GHD into adulthood if necessary). Acceptable diagnostic criteria include:
- •- insulin tolerance test (ITT): peak hGH = 5.0 ng/mL
- •- arginine alone: peak hGH = 1.4 ng/mL
- •- arginine + growth-hormone-releasing hormone
- •- glucagon stimulation test: peak hGH = 3.0 ng/mL
- •- at least 3 pituitary hormone deficiencies and a low IGF-I for age/gender
- •For arginine + GHRH stimulation test, peak hGH limit is based upon body mass index as follows: = 11.0 ng/mL for BMI < 25 kg/m2; = 8.0 ng/mL for 25 = BMI < 30 kg/m2; = 4.0 ng/mL for BMI = 30 kg/m2.
- •Current height may be used to determine BMI if BMI is not available from the date of the stimulation test.
- •If documented confirmation is not available, GH stimulation test may be performed at Screening (subjects receiving daily rhGH therapy must be withdrawn for at least 7 days prior to testing).
- •5. Subjects taking other hormone replacement therapy for pituitary failure must have been on a stable course of treatment for at least 3 months prior to Screening.
- •6. Subjects with underlying disorders responsible for the subject's GHD must have been clinically stable for at least 6 months prior to Screening.
- •7. If a subject is currently receiving daily recombinant human growth hormone (rhGH) injections for treatment of GHD, must agree to stop taking prescribed daily rhGH therapy for the washout period of 14 days minimum.
- •8. Subjects must agree to inform the prescribing physician of study involvement, and the Investigator, prior to initiating a new medication (prescription or over-the-counter).
- •9. Subjects must provide signed informed consent.
- •10. Subjects must have a BMI (kg/m2) between 19.0 and 35.0 (inclusive).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 38
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •1.Subjects with a documented history of diabetes mellitus or inadequate glucose control as defined by a historical or Screening value of:
- •FPG > 126 mg/dL (7 mM), or
- •HbA1c = 6.5%
- •2.Subjects with untreated adrenal insufficiency. Adrenal insufficiency will be screened by morning serum cortisol followed by ACTH stimulation test for subjects without documented history of adrenal insufficiency.
- •3.Subjects with free thyroxine outside the normal reference range.
- •4.Subjects currently taking oral glucocorticoids, except for physiological maintenance doses of oral glucocorticoids in subjects with multiple pituitary hormone deficiencies.
- •5.Subjects with current significant cardiovascular disease, heart insufficiency of NYHA class > 2.
- •6.Subjects with current significant cerebrovascular, pulmonary, neurological (not considered related to GHD), renal, inflammatory, or hepatobiliary disease.
- •7.Subjects with current papilledema.
- •8.Subjects with a history of persistent (unresolved without medical intervention) or recurring migraines.
- •9.Subjects with current edema (= CTCAE Grade 2).
- •10.Subjects with current drug or alcohol abuse.
- •11.Subjects with a documented history of HIV, current HBV or HCV infection (testing not required).
- •12.Subjects with a prior history of malignancy or abnormal results of any routine cancer screening tests, excluding adequately treated non-melanoma skin cancers or adequately treated in situ carcinoma of the cervix.
- •13.Women who are pregnant or breastfeeding.
- •14.Subjects treated with an investigational drug within 30 days prior to Screening.
- •15.Subjects with a significant abnormality in Screening laboratory results as interpreted by the Investigator and/or the Medical Monitor.
研究者
相似试验
进行中（未招募）
不适用
Phase II, open label, international, multicentre clinical trial to investigate safety and efficacy of oral ITF 2357 in patients with active systemic onset juvenile idiopathic arthritis SOJIA - NDEUCTR2006-000089-35-ITITALFARMACO16
进行中（未招募）
不适用
International, multicenter, open-label, phase II study to investigate the efficacy and safety of multiple doses of IMAB362 in patients with advanced adenocarcinoma of the stomach or the lower esophagus - IMAB362 clinical study phase IIa-01 - GM-IMAB-001-02EUCTR2009-017365-36-ATGANYMED Pharmaceuticals AG30
进行中（未招募）
1 期
International, multicenter, open-label, phase II study to investigate the efficacy and safety of multiple doses of IMAB362 in patients with advanced adenocarcinoma of the stomach or the lower esophagus - IMAB362 clinical study phase IIa-01 - GM-IMAB-001-02advanced adenocarcinoma of the stomach or the lower esophagusMedDRA version: 14.0Level: LLTClassification code 10001150Term: Adenocarcinoma gastricSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10001173Term: Adenocarcinoma of esophagusSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017365-36-BGGANYMED Pharmaceuticals AG54
进行中（未招募）
1 期
International, multicenter, open-label, phase II study to investigate the efficacy and safety of multiple doses of IMAB362 in patients with advanced adenocarcinoma of the stomach or the lower esophagusEUCTR2009-017365-36-LVGANYMED Pharmaceuticals AG30
进行中（未招募）
不适用
International, multicenter, open-label, phase II study to investigate the efficacy and safety of multiple doses of IMAB362 in patients with advanced adenocarcinoma of the stomach or the lower esophagus - IMAB362 clinical study phase IIa-01 - GM-IMAB-001-02advanced adenocarcinoma of the stomach or the lower esophagusMedDRA version: 14.1Level: LLTClassification code 10001173Term: Adenocarcinoma of esophagusSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10001150Term: Adenocarcinoma gastricSystem Organ Class: 100000004864EUCTR2009-017365-36-DEGANYMED Pharmaceuticals AG30